Table of Contents
To view the fulltext, log-in or choose pay-per-view options:
Get Access

Clinical Efficacy of Narrow-Band UVB (311 nm) Combined with Dithranol in Psoriasis

An Open Pilot Study

Carrozza P. · Häusermann P. · Nestle F.O. · Burg G. · Böni R.
Department of Dermatology, University Hospital Zurich, Switzerland Dermatology 2000;200:35–39 (DOI:10.1159/000018312)

Abstract

Background: For UVB, the most effective wavelength in clearing psoriatic lesions was found to be of 313 nm. The efficacy of whole body exposure to narrow-band UVB (311 nm) combined with dithranol in psoriasis has not been evaluated to date. Objective: Evaluation of the clinical efficacy of phototherapy with narrow-band UVB (311 nm) and dithranol for psoriasis by means of whole body exposures and analysis of the mean cumulative irradiation dose. Methods: In this open pilot study, 13 patients were treated for 4–5 weeks. Evaluation of the therapeutic efficacy was performed by comparing the Psoriasis Area and Severity Index (PASI) scores at baseline and after 4 weeks of treatment. The cumulative irradiation dose was also calculated. Results: Evaluation of the PASI scores showed a significant overall reduction of psoriatic lesions after 4 weeks of treatment. The cumulative irradiation dose was similar or lower to those found for phototherapy with narrow-band UVB alone. Discussion: In patients with widespread psoriasis, treatment with narrow-band UVB (311 nm) combined with dithranol is safe and effective, allowing reduction of the cumulative irradiation dose.

Copyright ® 2000 S.Karger AG, Basel

 

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50